Arcus Biosciences (NYSE:RCUS) CAO Sells $96,631.75 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 4,343 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $22.25, for a total transaction of $96,631.75. Following the transaction, the chief accounting officer directly owned 18,531 shares in the company, valued at approximately $412,314.75. The trade was a 18.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alexander Azoy also recently made the following trade(s):

• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total transaction of $46,824.08.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The shares were sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The shares were sold at an average price of $26.00, for a total value of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The stock was sold at an average price of $13.00, for a total transaction of $36,803.00.

Arcus Biosciences Price Performance

Shares of NYSE RCUS traded down $0.26 during midday trading on Thursday, reaching $22.02. 1,175,874 shares of the company traded hands, compared to its average volume of 1,200,446. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $26.40. The stock’s 50-day simple moving average is $20.82 and its 200-day simple moving average is $13.98.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same period last year, the company posted ($1.00) earnings per share. The firm’s quarterly revenue was down 45.8% compared to the same quarter last year. As a group, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on RCUS. Wells Fargo & Company increased their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 20th. Bank of America boosted their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average target price of $28.89.

Institutional Trading of Arcus Biosciences

Several institutional investors have recently modified their holdings of RCUS. Woodline Partners LP increased its position in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after purchasing an additional 1,603,367 shares during the period. Vanguard Group Inc. boosted its holdings in Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after acquiring an additional 1,298,584 shares in the last quarter. RA Capital Management L.P. acquired a new position in Arcus Biosciences during the first quarter worth $8,920,000. Wellington Management Group LLP acquired a new stake in shares of Arcus Biosciences in the 1st quarter worth about $8,500,000. Finally, Bank of America Corp DE boosted its position in shares of Arcus Biosciences by 173.5% during the third quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock valued at $18,507,000 after buying an additional 863,162 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.